Having trouble viewing this email? View in your browser.

26 January 2021

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.


ECCMID 2021 Abstract submission – less than a month to go!

Abstract submission for the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is now open!

Visit the ECCMID Abstract Website to view the abstract guidelines and to submit your work for inclusion in the world’s premier meeting in the field of infection.

Be sure to watch the Abstract Submission Tutorial before starting your submission.

Abstracts will be accepted until the deadline on 24 February 2021 at 15:59 CET.

› Read more

ECCMID Travel Grants – Apply when submitting your abstract

Each year ESCMID offers over 100 young scientist members who submit an abstract an ECCMID Travel Grant covering full registration to the congress and a travel allowance of EUR 500. The application for ECCMID 2021 Travel Grants are now open, in line with the ECCMID abstract submission.

Application for a travel grant must be indicated during the abstract submission process. The presenting author is the one who is eligible for the grant.

Find out more about eligibility on the
ECCMID Awards and Grants website.

› Read more

One more week to comment on the manuscript “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2020”

The deadline to provide feedback on the draft version of the “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2020” is 1 February 2021.

ESCMID members wishing to comment on the manuscript should write to guidancedocuments@escmid.org indicating their ESCMID membership number. 

You will receive the confidential manuscript, along with the comments form for listing feedback and the together with the template to register their comments and the AGREE GLOBAL RATING SCALE form to be completed (More information about the AGREE II tool can be found here).

Based on the comments received, the ESCMID Executive Committee will decide on whether to grant ESCMID endorsement to this document or not.

For more information please visit: 

› Read more

The 4th edition of the Laboratory Biosafety Manual 4th edition (LBM4) is now available online

The WHO has just published the new version of its Laboratory Biosafety Manual (LBM4). 

With particular emphasis on evidence, local biological risk assessment and personnel competence, the LBM4 presents a novel approach that allows each facility to take a feasible and most effective combination of risk control measures. This technology-neutral approach will help attain much desired equitable, adequate, and sustainable access to necessary laboratory services and life science research across all countries, without compromising safety.

You can download the publication here

› Read more

EU-JAMRAI launches Micro-Combat game App

With the aim of making the youngest generations aware of the antibiotic resistance problem and thus preventing it from worsening in the future, the European Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI) designed the Micro-Combat game App, a didactic card game that allows become familiar with the appropriate use of these medicines in a playful way.

Micro-Combat App is a cooperative game designed for players 10 years and older,  with an approximate duration of 15 minutes. It can be used in classroom or anywhere and, among other concepts, it allows introducing what types of pathogens we are exposed to, how we can prevent the spread of infectious diseases, how much more effective is prevention than the subsequent treatment of diseases or what antibiotic resistance is.

› Read more

ESCMID Research Grants awarded!

We are pleased to have awarded the 2021 ESCMID research grants this past week! 15 winning projects have been selected out of 94 excellent applications dealing with fungal, viral, and parasitic infections and diseases. Parasitology topics made a large impression comprising 7 of the 15 winning projects. Of the remaining 8 winning projects, 5 were in virology (2 for COVID-19) and 3 were in Mycology. We also note that 80% of the 15 winning projects had female applicants and were spread across 11 different countries. Congratulations to everyone that was awarded a grant, and we look forward to seeing the results in the future!

› Read more

New ESCMID Society Brochure online

A new and updated ESCMID Brochure has been published, and is perfect for letting your friends and colleagues know what the society is all about!

The 20-page booklet outlines all of the great initiatives, events and groups that make ESCMID the leading society in infectious diseases and clinical microbiology.

You can view the brochure on the ESCMID website.

› Read more

CMI highlight: Antibody persistence in the first six months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study

This study aimed at longitudinally evaluating the persistence of humoral immunity up to six months in a cohort of hospital employees with mild COVID-19.

Authors measured anti-RBD, -N and neutralizing antibodies at one, three and six months after mostly mild COVID-19 in 200 hospital workers using commercial ELISAs and a surrogate virus neutralization assay.

From the results obtained emerged that SARS-CoV-2-specific antibodies persisted in all participants up to 6 months. Anti-RBD geometric mean concentrations (GMCs) progressively increased between month one, three and six in the whole cohort. Anti-N antibodies were always detectable in >97%. Neutralizing antibodies were detectable in 99.5% of participants at six months post infection. Disease severity was associated with higher initial anti-RBD and RBD-ACE2 inhibiting antibody titers, but not with their kinetics.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.